Chief Development Officer
Tris Pharma, Inc.
Monmouth Junction, New Jersey
Dr. Lesnick joined Tris in 2023 to lead development of the company’s novel pipeline of investigational therapies. He has deep experience in managing global research and development programs from pre-clinical stage through Phase 3. His background spans a number of therapeutic categories, including psychiatry, infectious disease, endocrinology, oncology and allergy. Before co-founding Park Therapeutics, Marc held various executive roles at Spruce Biosciences, QED Therapeutics, Cascadian Therapeutics and Shionogi, Inc., among others, where he focused heavily on regulatory affairs and quality assurance, successfully progressing numerous clinical programs through to U.S. FDA and ex-U.S. approvals. Marc earned his B.S. degree in Biochemistry and Molecular Biology from the University of California, Santa Cruz and completed his Ph.D. in Biology at the University of Oregon.
Thursday, September 4, 2025
4:00 PM - 5:30 PM PST